Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells

Clinical Immunology

Volumn 155, Issue 2, 2014, Pages 160-175

  Wang, Yao ^a   Zhang, Wen ying ^a   Han, Qing wang ^a   Liu, Yang ^a   Dai, Han ren ^a   Guo, Ye lei ^a   Bo, Jian ^a   Fan, Hui ^a   Zhang, Yan ^a   Zhang, Ya jing ^a   Chen, Mei xia ^a   Feng, Kai chao ^a   Wang, Quan shun ^a   Fu, Xiao bing ^a   Han, Wei dong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Anti CD20 chimeric antigen receptor (CAR) T cells; ; Delayed toxicities; Diffuse large B cell lymphoma (DLBCL); ; Refractory advanced;

Indexed keywords

CARBOPLATIN; CD137 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD3ZETA ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETANERCEPT; ETOPOSIDE; GAMMA INTERFERON; GEMCITABINE; GLUCOCORTICOID; GRANZYME A; IFOSFAMIDE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 2; INTERLEUKIN 6; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VINCRISTINE; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN BINDING; T LYMPHOCYTE RECEPTOR;

ACUTE TOXICITY; ADOPTIVE TRANSFER; ADULT; ADVANCED CANCER; AGED; ARTICLE; B LYMPHOCYTE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER REGRESSION; CAPILLARY LEAK SYNDROME; CD20 DIRECTED CHIMERIC ANTIGEN RECEPTOR MODIFIED T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; DIGESTIVE SYSTEM; DIGESTIVE SYSTEM HEMORRHAGE; DISEASE DURATION; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; EFFUSION; FEMALE; FEVER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MALE; MIDDLE AGED; MUCOSAL NECROSIS; MULTIMODALITY CANCER THERAPY; OXYGEN THERAPY; PETECHIA; PNEUMONIA; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY DISTRESS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE; TUMOR CELL DESTRUCTION; TUMOR VOLUME; VERY ELDERLY; ADOPTIVE IMMUNOTHERAPY; CANCER STAGING; CELL LINE; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY; GENE DOSAGE; GENE ORDER; GENETICS; IMMUNOLOGY; LYMPHOCYTE COUNT; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIGENS, CD137; ANTIGENS, CD20; CELL LINE; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE DOSAGE; GENE ORDER; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE COUNT; LYMPHOMA, LARGE B-CELL, DIFFUSE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84908299844     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.10.002     Document Type: Article

References (44)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997, 89:3909-3918.
2. Jaffe E.S. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematol. Educ. Program Am. Soc. Hematol. Am. Soc. Hematol. Educ. Program 2009, 523-531.
3. Maloney D.G. Anti-CD20 antibody therapy for B-cell lymphomas. N. Engl. J. Med. 2012, 366:2008-2016.
4. Cultrera J.L., Dalia S.M. Diffuse large B-cell lymphoma: current strategies and future directions. Cancer Control 2012, 19:204-213.
5. Ruella M., Kalos M. Adoptive immunotherapy for cancer. Immunol. Rev. 2014, 257:14-38.
6. Barrett D.M., Singh N., Porter D.L., Grupp S.A., June C.H. Chimeric antigen receptor therapy for cancer. Annu. Rev. Med. 2014, 65:333-347.
7. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., Teachey D.T., Chew A., Hauck B., Wright J.F., Milone M.C., Levine B.L., June C.H. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013, 368:1509-1518.
8. Kochenderfer J.N., Dudley M.E., Carpenter R.O., Kassim S.H., Rose J.J., Telford W.G., Hakim F.T., Halverson D.C., Fowler D.H., Hardy N.M., Mato A.R., Hickstein D.D., Gea-Banacloche J.C., Pavletic S.Z., Sportes C., Maric I., Feldman S.A., Hansen B.G., Wilder J.S., Blacklock-Schuver B., Jena B., Bishop M.R., Gress R.E., Rosenberg S.A. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013, 122:4129-4139.
9. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011, 365:725-733.
10. Kochenderfer J.N., Dudley M.E., Feldman S.A., Wilson W.H., Spaner D.E., Maric I., Stetler-Stevenson M., Phan G.Q., Hughes M.S., Sherry R.M., Yang J.C., Kammula U.S., Devillier L., Carpenter R., Nathan D.A., Morgan R.A., Laurencot C., Rosenberg S.A. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
11. Kochenderfer J.N., Rosenberg S.A. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 2013, 10:267-276.
12. Savoldo B., Ramos C.A., Liu E., Mims M.P., Keating M.J., Carrum G., Kamble R.T., Bollard C.M., Gee A.P., Mei Z., Liu H., Grilley B., Rooney C.M., Heslop H.E., Brenner M.K., Dotti G. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 2011, 121:1822-1826.
13. Kochenderfer James N., Dudley Mark E., Kassim Sadik H., et al. Effective treatment of chemotherapy-refractory diffuse large B-cell lymphoma with autologous T cells genetically-engineered to express an anti-CD19 Chimeric Antigen Receptor 2013, ASH.
14. Till B.G., Jensen M.C., Wang J., Qian X., Gopal A.K., Maloney D.G., Lindgren C.G., Lin Y., Pagel J.M., Budde L.E., Raubitschek A., Forman S.J., Greenberg P.D., Riddell S.R., Press O.W. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012, 119:3940-3950.
15. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., Hillmen P., Keating M.J., Montserrat E., Rai K.R., Kipps T.J. L. International Workshop on Chronic Lymphocytic, Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
16. Wang Y., Bo J., Dai H.R., Lu X.C., Lv H.Y., Yang B., Wang T., Han W.D. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo. Exp. Hematol. 2013, 41:241-252. (e243).
17. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., Wunderlich J., Restifo N.P., Thomasian A., Downey S.G., Smith F.O., Klapper J., Morton K., Laurencot C., White D.E., Rosenberg S.A. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26:5233-5239.
18. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
19. Brentjens R.J., Riviere I., Park J.H., Davila M.L., Wang X., Stefanski J., Taylor C., Yeh R., Bartido S., Borquez-Ojeda O., Olszewska M., Bernal Y., Pegram H., Przybylowski M., Hollyman D., Usachenko Y., Pirraglia D., Hosey J., Santos E., Halton E., Maslak P., Scheinberg D., Jurcic J., Heaney M., Heller G., Frattini M., Sadelain M. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
20. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., Citrin D.E., Restifo N.P., Robbins P.F., Wunderlich J.R., Morton K.E., Laurencot C.M., Steinberg S.M., White D.E., Dudley M.E. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 2011, 17:4550-4557.
21. Ramakrishnan R., Assudani D., Nagaraj S., Hunter T., Cho H.I., Antonia S., Altiok S., Celis E., Gabrilovich D.I. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J. Clin. Invest. 2010, 120:1111-1124.
22. Klebanoff C.A., Khong H.T., Antony P.A., Palmer D.C., Restifo N.P. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005, 26:111-117.
23. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 2008, 8:59-73.
24. Song D.G., Ye Q., Carpenito C., Poussin M., Wang L.P., Ji C., Figini M., June C.H., Coukos G., Powell D.J. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011, 71:4617-4627.
25. Milone M.C., Fish J.D., Carpenito C., Carroll R.G., Binder G.K., Teachey D., Samanta M., Lakhal M., Gloss B., Danet-Desnoyers G., Campana D., Riley J.L., Grupp S.A., June C.H. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 2009, 17:1453-1464.
26. Khouri I.F., Saliba R.M., Giralt S.A., Lee M.S., Okoroji G.J., Hagemeister F.B., Korbling M., Younes A., Ippoliti C., Gajewski J.L., McLaughlin P., Anderlini P., Donato M.L., Cabanillas F.F., Champlin R.E. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001, 98:3595-3599.
27. Besser M.J., Shapira-Frommer R., Treves A.J., Zippel D., Itzhaki O., Hershkovitz L., Levy D., Kubi A., Hovav E., Chermoshniuk N., Shalmon B., Hardan I., Catane R., Markel G., Apter S., Ben-Nun A., Kuchuk I., Shimoni A., Nagler A., Schachter J. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 2010, 16:2646-2655.
28. Turtle C.J., Swanson H.M., Fujii N., Estey E.H., Riddell S.R. A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. Immunity 2009, 31:834-844.
29. Gattinoni L., Lugli E., Ji Y., Pos Z., Paulos C.M., Quigley M.F., Almeida J.R., Gostick E., Yu Z., Carpenito C., Wang E., Douek D.C., Price D.A., June C.H., Marincola F.M., Roederer M., Restifo N.P. A human memory T cell subset with stem cell-like properties. Nat. Med. 2011, 17:1290-1297.
30. Buchholz V.R., Neuenhahn M., Busch D.H. CD8+ T cell differentiation in the aging immune system: until the last clone standing. Curr. Opin. Immunol. 2011, 23:549-554.
31. Grossman W.J., Verbsky J.W., Barchet W., Colonna M., Atkinson J.P., Ley T.J. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004, 21:589-601.
32. Curtin J.F., Candolfi M., Fakhouri T.M., Liu C., Alden A., Edwards M., Lowenstein P.R., Castro M.G. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One 2008, 3:e1983.
33. Kalos M., Levine B.L., Porter D.L., Katz S., Grupp S.A., Bagg A., June C.H. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 2011, 3:95ra73.
34. Hinrichs C.S., Palmer D.C., Rosenberg S.A., Restifo N.P. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. J. Immunother. 2005, 28:517-524.
35. Berger C., Jensen M.C., Lansdorp P.M., Gough M., Elliott C., Riddell S.R. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 2008, 118:294-305.
36. Louis C.U., Savoldo B., Dotti G., Pule M., Yvon E., Myers G.D., Rossig C., Russell H.V., Diouf O., Liu E., Liu H., Wu M.F., Gee A.P., Mei Z., Rooney C.M., Heslop H.E., Brenner M.K. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011, 118:6050-6056.
37. Brentjens R.J., Davila M.L., Riviere I., Park J., Wang X., Cowell L.G., Bartido S., Stefanski J., Taylor C., Olszewska M., Borquez-Ojeda O., Qu J., Wasielewska T., He Q., Bernal Y., Rijo I.V., Hedvat C., Kobos R., Curran K., Steinherz P., Jurcic J., Rosenblat T., Maslak P., Frattini M., Sadelain M. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 2013, 5:177ra138.
38. Lamers C.H., Sleijfer S., van Steenbergen S., van Elzakker P., van Krimpen B., Groot C., Vulto A., den Bakker M., Oosterwijk E., Debets R., Gratama J.W. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 2013, 21:904-912.
39. Morgan R.A., Yang J.C., Kitano M., Dudley M.E., Laurencot C.M., Rosenberg S.A. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 2010, 18:843-851.
40. Watanabe Keisuke, Terakura Seitaro, Goto Tatsunori Anti-CD20 chimeric antigen receptor transduced T cells can recognize very low antigen expression: determination of the lower threshold required to activate the CAR-T cells. ASH 2013.
41. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3:133-146.
42. Teachey D.T., Rheingold S.R., Maude S.L., Zugmaier G., Barrett D.M., Seif A.E., Nichols K.E., Suppa E.K., Kalos M., Berg R.A., Fitzgerald J.C., Aplenc R., Gore L., Grupp S.A. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013, 121:5154-5157.
43. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
44. Lankford C.S., Frucht D.M. A unique role for IL-23 in promoting cellular immunity. J. Leukoc. Biol. 2003, 73:49-56.